Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 21
2022 63
2023 21
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

64 results

Results by year

Filters applied: . Clear all
Page 1
A Nitrite Excipient Database: A Useful Tool to Support N-Nitrosamine Risk Assessments for Drug Products.
Boetzel R, Schlingemann J, Hickert S, Korn C, Kocks G, Luck B, Blom G, Harrison M, François M, Allain L, Wu Y, Bousraf Y. Boetzel R, et al. J Pharm Sci. 2023 Jun;112(6):1615-1624. doi: 10.1016/j.xphs.2022.04.016. Epub 2022 Apr 29. J Pharm Sci. 2023. PMID: 35500671 Free article.
The major findings from the database analyses are: (1) average nitrite content and batch to batch variance differ among excipients, (2) for solid dosage forms, the nitrite contribution is dominated by the highest formula % excipients, e.g., the fillers (diluents), which ar …
The major findings from the database analyses are: (1) average nitrite content and batch to batch variance differ among excipients, (2) for …
Ensuring Product Stability - Choosing the Right Excipients.
Veronica N, Heng PWS, Liew CV. Veronica N, et al. J Pharm Sci. 2022 Aug;111(8):2158-2171. doi: 10.1016/j.xphs.2022.05.001. Epub 2022 May 6. J Pharm Sci. 2022. PMID: 35526577 Review.
More specifically, the mechanisms by which excipients can reduce drug degradation (e.g. acting as a physical barrier, reducing moisture availability and mobility) are discussed. ...
More specifically, the mechanisms by which excipients can reduce drug degradation (e.g. acting as a physical barrier, reducing moistu …
Pharmaceutical Forced Degradation (Stress Testing) Endpoints: A Scientific Rationale and Industry Perspective.
Zelesky T, Baertschi SW, Foti C, Allain LR, Hostyn S, Franca JR, Li Y, Marden S, Mohan S, Ultramari M, Huang Z, Adams N, Campbell JM, Jansen PJ, Kotoni D, Laue C. Zelesky T, et al. J Pharm Sci. 2023 Dec;112(12):2948-2964. doi: 10.1016/j.xphs.2023.09.003. Epub 2023 Sep 9. J Pharm Sci. 2023. PMID: 37690775 Review.
These two endpoints are 1) a % total degradation target outcome (e.g., for "reactive" drugs) or, 2) a specified amount of stress, even in the absence of any degradation (e.g., for "stable" drugs). ...The experimental data set, derived from the Campbell et al. (20 …
These two endpoints are 1) a % total degradation target outcome (e.g., for "reactive" drugs) or, 2) a specified amount of stress, eve …
Development of Prodrugs for Treatment of Parkinson's Disease: New Inorganic Scaffolds for Blood-Brain Barrier Permeation.
Di Battista V, Hey-Hawkins E. Di Battista V, et al. J Pharm Sci. 2022 May;111(5):1262-1279. doi: 10.1016/j.xphs.2022.02.005. Epub 2022 Feb 17. J Pharm Sci. 2022. PMID: 35182542 Review.
However, it is well known that prolonged treatment with L-DOPA leads to several side effects, which may affect the patient's life expectancy (i.e., the wearing-off phenomenon, on-off fluctuations, and dyskinesia). ...
However, it is well known that prolonged treatment with L-DOPA leads to several side effects, which may affect the patient's life expectancy …
Platform for the Delivery of Unformulated RNA In Vivo.
France MM, Rio TD, Travers H, Raftery E, Langer R, Traverso G, Schoellhammer CM. France MM, et al. J Pharm Sci. 2022 Jun;111(6):1770-1775. doi: 10.1016/j.xphs.2021.12.008. Epub 2021 Dec 11. J Pharm Sci. 2022. PMID: 34906584
Particles in Biopharmaceutical Formulations, Part 2: An Update on Analytical Techniques and Applications for Therapeutic Proteins, Viruses, Vaccines and Cells.
Roesch A, Zölls S, Stadler D, Helbig C, Wuchner K, Kersten G, Hawe A, Jiskoot W, Menzen T. Roesch A, et al. J Pharm Sci. 2022 Apr;111(4):933-950. doi: 10.1016/j.xphs.2021.12.011. Epub 2021 Dec 14. J Pharm Sci. 2022. PMID: 34919969 Free article. Review.
Technical improvements, new analytical developments and emerging tools (e.g., machine learning tools) increase the amount of information generated for particles. ...
Technical improvements, new analytical developments and emerging tools (e.g., machine learning tools) increase the amount of informat …
Drug Formulations for Localized Treatment of Human Papillomavirus-Induced Lesions.
Maocha IG, Carvalho J, Lopes-Nunes J, Rosado T, Gallardo E, Tomás M, Palmeira-de-Oliveira A, Palmeira-de-Oliveira R, Martinez-de-Oliveira J, Campello MPC, Paulo A, Cruz C. Maocha IG, et al. J Pharm Sci. 2022 Aug;111(8):2230-2238. doi: 10.1016/j.xphs.2022.02.004. Epub 2022 Feb 17. J Pharm Sci. 2022. PMID: 35182543 Free article.
Coupled Diffusion-Binding-Deformation Modelling for Phase-Transition Microneedles-Based Drug Delivery.
Yadav PR, Das DB, Pattanayek SK. Yadav PR, et al. J Pharm Sci. 2023 Apr;112(4):1108-1118. doi: 10.1016/j.xphs.2022.12.009. Epub 2022 Dec 15. J Pharm Sci. 2023. PMID: 36528111
In addressing this point, we have developed a coupled diffusion-binding-deformation model to understand the effect of physicochemical parameters (e.g., swelling capacity, drug binding) of MN and skin mechanical properties on overall drug transport behaviour. ...
In addressing this point, we have developed a coupled diffusion-binding-deformation model to understand the effect of physicochemical parame …
64 results